Anthony R. Mato, MD, MSCE

Anthony R. Mato, MD, MSCE, is an associate member and director of the Chronic Lymphocytic Leukemia (CLL) Program at Memorial Sloan Kettering Cancer Center. He received his medical degree from the State University of New York at Buffalo, and he completed his internal medicine residency and hematology/oncology fellowship at the Hospital of the University of Pennsylvania. While at Penn, Dr Mato also earned a master’s degree in clinical epidemiology. 

His research on the development of clinical and translational trials for patients with CLL and lymphoproliferative disorders focuses on novel immunotherapies, signal transduction inhibitors, immune checkpoint inhibitors, and immunotherapy agents. His outcomes-related research explores a wide variety of health indicators among patients with CLL in real-world settings. Dr Mato has been the principal investigator for numerous clinical trials for patients with CLL and is currently overseeing several ongoing clinical trials, some of which are actively enrolling patients. 

A well-published scholar, he regularly contributes articles to peer-reviewed journals, including Blood, the British Journal of Haematology, the Annals of Oncology, Haematologica, Lancet Oncology, and the American Journal of Hematology. Dr Mato is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physician Executives. He is also on the medical advisory board of the CLL Society, a patient-centric, physician-curated nonprofit organization that focuses on patient education and support.